生物
效应器
转录组
癌症研究
免疫疗法
趋化因子
细胞
肿瘤浸润淋巴细胞
免疫系统
免疫学
基因
基因表达
遗传学
作者
Marco De Simone,Alberto Arrigoni,Grazisa Rossetti,Paola Gruarin,Valeria Ranzani,Claudia Politano,Raoul J.P. Bonnal,Elena Provasi,Maria Lucia Sarnicola,Ilaria Panzeri,Monica Moro,Mariacristina Crosti,Saveria Mazzara,Valentina Vaira,Silvano Bòsari,A. Palleschi,L. Santambrogio,Giorgio Bovo,Nicola Zucchini,Mauro Totis
出处
期刊:Immunity
[Cell Press]
日期:2016-11-01
卷期号:45 (5): 1135-1147
被引量:599
标识
DOI:10.1016/j.immuni.2016.10.021
摘要
Tumor-infiltrating regulatory T lymphocytes (Treg) can suppress effector T cells specific for tumor antigens. Deeper molecular definitions of tumor-infiltrating-lymphocytes could thus offer therapeutic opportunities. Transcriptomes of T helper 1 (Th1), Th17, and Treg cells infiltrating colorectal or non-small-cell lung cancers were compared to transcriptomes of the same subsets from normal tissues and validated at the single-cell level. We found that tumor-infiltrating Treg cells were highly suppressive, upregulated several immune-checkpoints, and expressed on the cell surfaces specific signature molecules such as interleukin-1 receptor 2 (IL1R2), programmed death (PD)-1 Ligand1, PD-1 Ligand2, and CCR8 chemokine, which were not previously described on Treg cells. Remarkably, high expression in whole-tumor samples of Treg cell signature genes, such as LAYN, MAGEH1, or CCR8, correlated with poor prognosis. Our findings provide insights into the molecular identity and functions of human tumor-infiltrating Treg cells and define potential targets for tumor immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI